Desmedt et al. revealed that different breast cancer subtypes show different prognostic gene signatures, and that the strong prognostic impact of proliferation-related gene signatures is restricted to estrogen receptor-positive, HER2-negative (ER+/HER2−) breast cancer14. The gene discussed is ERBB2; the disease is breast cancer.